Multiple myeloma in the very elderly patient: challenges and solutions - Wikidata - wikimedia - TriplyDB

Multiple myeloma in the very elderly patient: challenges and solutions

Multiple myeloma in the very elderly patient: challenges and solutions

http://www.wikidata.org/entity/Q26752991

about

Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.Treat or palliate: outcomes of very elderly myeloma patients.

P2860

Q37108574-91B4BDF6-9B9D-419F-B93E-BBE877983C44 Q49868035-4A6CE327-B75D-4E11-80C6-CF059A03CFE6

P2860

Multiple myeloma in the very elderly patient: challenges and solutions

http://www.wikidata.org/entity/Q26752991

description

2016 nî lūn-bûn

@nan

2016 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Multiple myeloma in the very elderly patient: challenges and solutions

@ast

Multiple myeloma in the very elderly patient: challenges and solutions

@en

Multiple myeloma in the very elderly patient: challenges and solutions

@nl

type

label

Multiple myeloma in the very elderly patient: challenges and solutions

@ast

Multiple myeloma in the very elderly patient: challenges and solutions

@en

Multiple myeloma in the very elderly patient: challenges and solutions

@nl

prefLabel

Multiple myeloma in the very elderly patient: challenges and solutions

@ast

Multiple myeloma in the very elderly patient: challenges and solutions

@en

Multiple myeloma in the very elderly patient: challenges and solutions

@nl

P1433

Q26752991-620AB63A-EA65-4D51-B63A-847FE6287C93

P1476

Q26752991-D5E6E3D5-0223-4A0B-AF91-5CC59817397A

P2093

Q26752991-5ABBD60F-974D-4CDD-A4FF-0EE4CEB4CF63

Q26752991-6BCDBB70-C429-484F-89B0-D260A5370A55

Q26752991-72ACD8E9-D209-48AC-B66D-BECBB9C5E510

Q26752991-951B6AE9-F16A-4412-BC77-E9C922C5C15F

P275

Q26752991-8F1FFFF0-1C05-4295-874B-18612EE152CD

P2860

Q26752991-0234275B-41AA-4CA5-BBAC-9DF7D45DCED1

Q26752991-03DF07E1-791B-4E86-A8A0-E6A39F2C2762

Q26752991-06CF224C-71EE-4865-B4F3-4E3E0ACAEB01

Q26752991-082F1570-94A2-4CCD-B204-4B0A2A5E83C0

Q26752991-0FD119A6-A5B2-43DC-8347-AC07558E7901

Q26752991-1061BD2D-B15C-4F3E-9CFA-05823A4E9AA7

Q26752991-1094C235-B219-4987-B603-1A30A6934CF6

Q26752991-125BE95B-BD40-4419-AB91-5FC75409BC84

Q26752991-13ABDD0B-C417-4C00-A8DC-A506C5C7418F

Q26752991-19FED3FA-C6E6-4653-9B21-F108C15FCE29

P304

Q26752991-21652CA3-1E06-4015-B679-58915247D380

P31

Q26752991-434BEB53-3633-4027-A9DB-59E6256ACD8C

Q26752991-D17CD075-FC54-436A-9F54-1E6ACB219984

P3181

Q26752991-D7D88523-CAA3-4BD4-AA36-E21A960BF2C3

P356

Q26752991-9D78D7EA-0971-42F8-8768-A2241BC6C6EC

P407

Q26752991-336EF2B0-312E-4DEB-A50E-2749A0E8FA7E

P478

Q26752991-342D4BD5-4122-46DE-A754-74AD9674F854

P50

Q26752991-443C2FD8-650A-4CCC-A09B-C3848351D75C

Q26752991-F59561C8-AF16-44B9-87FD-CBB54B9E6161

P5008

Q26752991-B93231BF-1AAE-4C6B-BB86-DCC20D898CEF

P577

Q26752991-DA33ED92-2F5D-4F39-8AEA-2CA6D0BD9AE5

P698

Q26752991-1555EAEB-419F-4873-915F-8B403A46EB34

P921

Q26752991-8A188BC2-A298-4BD1-825D-0557F02E5225

Q26752991-B9B6417A-A7E4-4E16-B641-0FE35F66C38D

P932

Q26752991-B3E2645A-6018-49DF-AB4C-C9F8FE809CBC

P3181

P356

P1433

Clinical Interventions in Aging

P1476

Multiple myeloma in the very elderly patient: challenges and solutions

@en

P2093

Andrew J King

http://www.w3.org/2001/XMLSchema#string

Caroline Watson

http://www.w3.org/2001/XMLSchema#string

Faye Sharpley

http://www.w3.org/2001/XMLSchema#string

Toby A Eyre

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials.

Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network

International staging system for multiple myeloma.

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Prevalence of monoclonal gammopathy of undetermined significance.

P304

423-435

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2279158

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/CIA.S89465

http://www.w3.org/2001/XMLSchema#string

P407

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Karthik Ramasamy

P5008

P577

2016-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27143866

http://www.w3.org/2001/XMLSchema#string

P921

multiple myeloma

hemic and immune systems

P932

4839967

http://www.w3.org/2001/XMLSchema#string